Graef Thorsten
Known title: Chief Medical OfficerCIK: 0001581192
Associated companies
Transaction History
| ARTV | ▲ Buy | Grant | 60,000 | $0 | 2/26/2025 | View on chart |
| ARTV | ▲ Buy | Grant | 20,000 | $0 | 9/12/2024 | View on chart |
| ARTV | ▲ Buy | Grant | 60,000 | $0 | 2/26/2025 | View on chart |
| ARTV | ▲ Buy | Grant | 20,000 | $0 | 9/12/2024 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
ARTV Announces Oral Presentation of AlloNK Data at Sjögren’s Symposium
Artiva Biotherapeutics will give an oral presentation of its AlloNK® clinical data at the 17th International Symposium on Sjögren’s Disease. The talk focuses on early results from a study in patients with this autoimmune disorder. The data could influence how investors view the company’s therapeutic pipeline. The presentation is a milestone before any formal publication or regulatory filing.
ARTV Announces Oral Presentation of AlloNK Data at Sjögren’s Symposium. Artiva Biotherapeutics will give an oral presentation of its AlloNK® clinical data at the 17th International Symposium on Sjögren’s Disease. The talk focuses on early results from a study in patients with this autoimmune disorder. The data could influence how investors view the company’s therapeutic pipeline. The presentation is a milestone before any formal publication or regulatory filing.